• AstraZeneca highlighted 21 late-stage new molecular entities, 183 development projects, 116 Phase II or Phase III NME or major lifecycle programs.
• Key 2026-2027 catalysts include Datroway lung Phase III readouts in H2 2026, Tagrisso-Orpathys SAFFRON data in H2 2026, PACIFIC-9 data in H2 2026.
• Regulatory decisions flagged for Datroway in metastatic TNBC in the EU, Japan, China, Imfinzi in high-risk non-muscle invasive bladder cancer in Japan, Truqap in PTEN-deficient mHSPC in the EU.
• Pipeline designations include 3 Priority Review, 5 Breakthrough or PRIME or Sakigake, 14 Fast Track, 22 Orphan, 3 Qualified Infectious Disease products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein.